Blood neurofilament light chain in Parkinson’s disease and atypical parkinsonisms: a protocol for systematic review and meta-analysis

Wang, HongZhou; Wang, WanHua; Shi, HaiCun; Han, Lijian; Pan, PingLei

doi:10.37766/inplasy2020.7.0091

Cited by 2 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a marker of neuroaxonal destruction involvement, sNfL is not specific for WD, but is elevated in many neurodegenerative and neuroinflammatory disorders 21‐26 . Similarly, the scales and markers of hepatic injury used in WD are not specific for WD 1,2,4,19 .…”

Section: Discussionmentioning

confidence: 99%

“…As a marker of neuroaxonal destruction involvement, sNfL is not specific for WD, but is elevated in many neurodegenerative and neuroinflammatory disorders. [21][22][23][24][25][26] Similarly, the scales and markers of hepatic injury used in WD are not specific for WD. 1,2,4,19 However, the concordance of our findings with the WD-specific UWDRS and brain MRI scale suggest that sNfL measures clinically relevant neurodestruction in WD.…”

Section: Discussionmentioning

confidence: 99%

“…Neurofilament light (NfL) is a cytoskeletal light chain that is released during neuroaxonal injury. [21][22][23][24][25][26] NfL concentration can be measured in cerebrospinal fluid (CSF) as well as serum, and in many neurological diseases demonstrating significant neuroaxonal destruction. [21][22][23][24][25][26] These results led to the inclusion of serum NfL (sNfL) concentration as a relevant biomarker in clinical studies.…”

Section: Serum Neurofilament Light Chain As a Biomarker Of Brain Inju...mentioning

confidence: 99%

“…[21][22][23][24][25][26] NfL concentration can be measured in cerebrospinal fluid (CSF) as well as serum, and in many neurological diseases demonstrating significant neuroaxonal destruction. [21][22][23][24][25][26] These results led to the inclusion of serum NfL (sNfL) concentration as a relevant biomarker in clinical studies. 24 Shribman et al described higher sNfL levels in WD patients with neurological presentation compared with a control group, as well as with WD patients with hepatic presentation, 27 warranting further analysis of sNfL in WD.…”

Section: Serum Neurofilament Light Chain As a Biomarker Of Brain Inju...mentioning

confidence: 99%

“…Neurofilament light (NfL) is a cytoskeletal light chain that is released during neuroaxonal injury 21‐26 . NfL concentration can be measured in cerebrospinal fluid (CSF) as well as serum, and in many neurological diseases demonstrating significant neuroaxonal destruction 21‐26 . These results led to the inclusion of serum NfL (sNfL) concentration as a relevant biomarker in clinical studies 24 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations

et al. 2022

View full text Add to dashboard Cite

Background: Clinical scales and neuroimaging are used to monitor nervous system injury in Wilson's disease, while data on serum markers are scarce. Objective: To investigate whether serum concentrations of neurofilament light chain (sNfL) correlate with brain injury in Wilson's disease patients. Methods: In 61 treatment-naïve patients, the Unified Wilson's Disease Rating Scale and a validated semiquantitative brain magnetic resonance imaging scale were compared with concentrations of sNfL. Results: Concentrations of sNfL were significantly higher in patients with neurological disease compared with patients presenting with other forms (39.7 AE 73.4 pg/mL vs. 13.3 AE 9.2 pg/mL; P < 0.01). Moreover, the sNfL concentration positively correlated with neurological severity scores and with acute and chronic brain damage based on the neuroimaging scale. Conclusions: Neurofilament light chain concentrations may be used as a marker of brain injury in Wilson's disease, in addition to the clinical and neuroimaging disease severity scales.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Serum Neurofilament Light Chain As a Biomarker Of Brain Inju...mentioning

confidence: 99%

Section: Serum Neurofilament Light Chain As a Biomarker Of Brain Inju...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations

et al. 2022

View full text Add to dashboard Cite

show abstract

The 2022 Lady Estelle Wolfson lectureship on neurofilaments

Petzold

2022

Journal of Neurochemistry

View full text Add to dashboard Cite

Neurofilament proteins (Nf) have been validated and established as a reliable body fluid biomarker for neurodegenerative pathology. This review covers seven Nf isoforms, Nf light (NfL), two splicing variants of Nf medium (NfM), two splicing variants of Nf heavy (NfH), -internexin (INA) and peripherin (PRPH). The genetic and epigenetic aspects of Nf are discussed as relevant for neurodegenerative diseases and oncology. The comprehensive list of mutations for all Nf isoforms covers Amyotrophic Lateral Sclerosis, Charcot-Marie Tooth disease, Spinal muscular atrophy, Parkinson Disease and Lewy Body Dementia. Next, emphasis is given to the expanding field of post-translational modifications (PTM) of the Nf amino acid residues. Protein structural aspects are reviewed alongside PTMs causing neurodegenerative pathology and human autoimmunity. Molecular visualisations of NF PTMs, assembly and stoichiometry make use of Alphafold2 modelling. The implications for Nf function on the cellular level and axonal transport are discussed. Neurofilament aggregate formation and proteolytic breakdown are reviewed as relevant for biomarker tests and disease.Likewise, Nf stoichiometry is reviewed with regard to in vitro experiments and as a compensatory mechanism in neurodegeneration. The review of Nf across a spectrum of 87 diseases from all parts of medicine is followed by a critical appraisal of 33

show abstract

Blood neurofilament light chain in Parkinson’s disease and atypical parkinsonisms: a protocol for systematic review and meta-analysis

Cited by 2 publications

References 0 publications

Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations

Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations

The 2022 Lady Estelle Wolfson lectureship on neurofilaments

Contact Info

Product

Resources

About